GERMANTOWN, Md. (TheStreet) -- Neuralstem (CUR - Get Report) is providing an overly optimistic picture about its surgical stem-cell therapy for amyotrophic lateral sclerosis (ALS), the degenerative and fatal nerve disease. <\/p>\n
Instead of disclosing the results from all 15 ALS patients enrolled in Neuralstem's phase II study of NSI-566, the company decided to only release a comparison between the patients who responded and those who didn't respond. Of course, the seven responders in the study showed more stabilization or improvements in muscle function compared with the eight patients deemed non-responders. <\/p>\n
The scientific term for this conclusion is, \"Duh.\" <\/p>\n
When you work backwards and do some simple math on the muscle performance of all 15 ALS patients in the Neuralstem study, the results aren't very encouraging. Neuralstem chose to stay mum on this more customary analysis. <\/p>\n
Neuralstem shares are down 14% to $3.21 in Thursday trading. <\/p>\n
<\/p>\n
Read the original here:<\/p>\n
Neuralstem Stock Plunges After Latest Study on ALS Drug<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" GERMANTOWN, Md. (TheStreet) -- Neuralstem (CUR - Get Report) is providing an overly optimistic picture about its surgical stem-cell therapy for amyotrophic lateral sclerosis (ALS), the degenerative and fatal nerve disease. Continue reading